Genomics driven precision oncology in advanced biliary tract cancer improves survival.

"these included mo_1347 a 46-year-old male with metastatic cca (and a history of ampullary carcinoma) previously treated with gemcitabine and cisplatin; a lymph node biopsy from this case histologically seen as poorly differentiated high-grade adenocarcinoma admixed with prominent inflammation was found to harbor 225 mutations/mb and high microsatellite instability (msi-high) score consistent with a biallelic loss of function of the mismatch repair deficiency gene msh2 (with truncating germline mutation msh2 c 2494g>t; p glu832ter; dbsnp: rs863225396) coupled with the somatic loss of heterozygosity through the splice acceptor mutation msh2 c 1662-1g>a."

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Grant Support: This work was supported by grants from the NCI Early Detection Research Network (U01CA214170) and NIH/NCI Outstanding Investigator Award (R35CA231996) Disclosures: MMZ – Institutional grant funding from AstraZeneca, MedImmune and Seattle Genetics. VS – Institutional grant funding from Agios, Bristol-Myers Squibb, Celgene, Clovis, Cornerstone, Exelixis, Fibrogen, Incyte, Ipsen, Medimmune, Merck, NCI, Rogel Cancer Center, Repare, Relay, Servier, Syros and Transthera; and consultant fees from AstraZeneca, Autem, Cornerstone, Delcath Systems, GlaxoSmithKline, Helsinn, Histosonics, Incyte, Ipsen, Kinnate, Lynx Group, QED, Servier and Taiho."